Ascendis Pharma Launches 2nd TransCon ™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ASND today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available…#denmark #yorvipath #transconpth #pth #austria #ascendispharma #transcon #janmikkelsen #vision3x3 #vision2030
Source: Reuters: Health - Category: Consumer Health News Source Type: news